Contents

1. Letter from the Director
2. Center Summary
3. Center Highlights
4. Faculty and Staff
5. Strategic Partnerships Across NYU Langone Health
6. Grants
7. Publications
8. Informing National Priorities in Policy and Practice
9. Events and Seminars
10. Education and Training
11. Pilot Project Grant Program
12. Other Center Highlights
13. Communications and Media
Letter from the Director

Magdalena Cerdá, DrPH, MPH
Director, Center for Opioid Epidemiology & Policy
Professor, Department of Population Health

In the five and a half years since its inception, the NYU Center for Opioid Epidemiology and Policy (COEP) has become a national leader in research addressing the overdose crisis. COEP’s faculty, students, postdoctoral fellows, and staff have made significant strides in promoting the use of science to identify feasible and effective policies and programs to reduce overdose and related harms through research, training, and dissemination. COEP members have generated over $18 million in funding and published 382 peer-reviewed publications.

Our prominent role in forecasting emerging trends in overdose, health service responses to opioid use disorder treatment, and evaluating overdose prevention policies has produced important publications on the leading solutions to the overdose crisis. This includes research on machine learning models to forecast community overdose hotspots, innovations in opioid use disorder treatment during the COVID-19 pandemic, the intended and unintended consequences that prescription opioid policies (e.g., prescription drug monitoring programs and pain management clinic laws) have had on opioid prescribing and overdose, as well as the role that cannabis legalization plays in shaping opioid use disorder and overdose among people with chronic pain.

Research published by COEP has received national attention and has impacted national policy. Our work on the impact of expanded methadone take-home flexibilities during the COVID-19 pandemic on patient experience and treatment engagement informed the new Substance Abuse and Mental Health Services Administration regulations on methadone prescribing and dispensing. Research on the impact that decriminalizing low-level drug possession in Oregon and Washington has had on arrests and overdose has been widely quoted in the popular press and is being used to inform state policy agendas across the country.

COEP also plays a prominent role in pushing forward the science of substance use disorder and harm reduction services to improve the health of people who use drugs. COEP research has shown, for example, that in the United States, up to 87% of people with opioid use disorder never receive treatment. COEP investigators are examining the types of services that are needed in emergency departments, primary care and specialty care to increase initiation and retention in evidence-based treatment for opioid use disorder. In the area of harm reduction, we launched the first federally funded evaluation of the effectiveness of overdose prevention centers in New York City and Rhode Island. COEP investigators also have research collaborations across the world, including in Chile, Colombia, Mexico, Uruguay, South Africa, France, Scotland, Australia, Ukraine, Russia, Greece and Cyprus, among others.
COEP is invested in promoting new work and new investigators in the field of overdose prevention. In the past 5 and a half years, COEP has established new collaborations across 6 clinical departments at NYU Langone Health, and the Institute for Excellence in Health Equity. COEP has been actively engaged in informing policy at the federal, state, and local levels, and has organized two major national conferences that helped mark and define key inflections in the field. Over 3,500 individuals have attended COEP’s 49 events.

As we look to the next five years, we are committed to promoting the use of science to understand the complex causes of and generate innovative solutions to the evolving overdose crisis. Working with a fantastic team of colleagues and partners across the country and world, I cannot wait to see what lies ahead.

Sincerely,

[Signature]
Center Summary

The Center for Opioid Epidemiology and Policy at NYU Langone Health launched in 2018 to serve as a central source of research on the rapidly shifting opioid overdose epidemic. Our aim is to inform promising policy, health services, community, and treatment approaches to reduce overdose and drug-related harms through these four areas of focus, overall and across intersectional subgroups:

- examining the social and policy drivers of population-level rates of overdose and disparities in overdose rates
- evaluating the impact of existing and novel service, policy and health service solutions to the epidemic to build health equity
- integrating advanced analytical and data science techniques with epidemiologic research to more precisely measure, forecast and understand the drivers of overdose and related harms
- investigate the links between drug use and related health and social concerns including violence, infectious disease and evolving crises

Center Highlights – 2018-Present

- $18,322,185 in Grant Funding
- 382 Publications
- 3,504 COEP Event Attendees
Faculty and Staff

The Center for Opioid Epidemiology and Policy works with a multidisciplinary group of faculty and staff who study the opioid epidemic as well as other areas of substance use and related health needs. Outside of the core group of 7 faculty from the NYU Department of Population Health, the Center engages 24 faculty affiliates throughout the NYU Grossman School of Medicine, as well as other local, national and global institutions.

Core faculty and their research area of focus include:

- **Magdalena Cerdá, DrPH, MPH**, Professor & Director, Center for Opioid Epidemiology and Policy – social inequality, drug policy, harm reduction, overdose, violence
- **Bennett Allen, PhD, MPA**, Assistant Professor – overdose, mental health, public health practice, criminal legal system
- **Amanda M. Bunting, PhD**, Assistant Professor – polysubstance use, overdose, mixed-methods, trauma
- **Samuel R. Friedman, PhD**, Research Professor – HIV and related infections, harm reduction, overdose, social determination of health, social networks
- **Noa Krawczyk, PhD**, Assistant Professor – health services and policy research, substance use treatment, harm reduction, integrating evidence-based practices in medical settings
- **Ellicott C. Matthay, PhD**, Assistant Professor – social inequality, causal inference, violence, cannabis policy
- **Suzan M. Walters, PhD**, Assistant Professor – intersectional stigma, HIV, harm reduction, social and structural determinants of health

Strategic Partnerships Across NYU Langone Health

COEP faculty have expanded the reach of the Center beyond the Department of Population Health. By convening the Substance Use Research Group, bringing together researchers across NYU Langone Health that are engaged in research related to substance use, COEP has developed strategic partnerships with affiliated faculty in 6 clinical departments, including the Departments of Anesthesiology, Perioperative Care and Pain Medicine, Emergency Medicine, Medicine, Psychiatry, and Surgery, and the Institute for Excellence in Health Equity (IEHE). Such collaborations have led to a P30 Center grant submission (1P30DA060805) in September 2023 that brought together faculty from the Departments of Population Health, Emergency Medicine, Psychiatry, Surgery, and IEHE; joint research grant proposals, as well as a number of funded joint grant awards already (e.g., R01 DA051509, R01 DA053243, R13 DA058520, 5UG1DA013035-22).
Grants

From 2018 to present, COEP faculty have been awarded over $18.3 million in grant funding, predominantly from the National Institutes of Health. The total value of current active awards is $24.6 million.

<table>
<thead>
<tr>
<th>Grants</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awarded Grants</td>
<td>$18,322,185</td>
</tr>
<tr>
<td>Current Active Awards</td>
<td>$24,669,733</td>
</tr>
</tbody>
</table>

Some of the notable recent federal agency grants awarded in the last several years include:

- **R01 – Comparative evaluation of Overdoes Prevention Centers (OPCs) in New York City and Rhode Island** (Cerda, Magdalena/Marshall, Brandon)
  
The objectives of this study are to 1) determine the individual- and neighborhood-level outcomes associated with implementation of OPCs in New York City and Rhode Island; and 2) examine the role that the local context plays in shaping the impact of OPCs.

- **R01 – Large Data Spatiotemporal Modeling of Optimal Combinations of Interventions to Reduce Opioid Harm in the United States** (Cerda, Magdalena/DiMaggio, Charles)
  
  This study aims to identify and make available evidence on the optimal combination of laws needed at the state and local level to reduce harms from overdoses, and the conditions that need to be put in place at the local level to maximize the impact of such laws.

- **R01 – Understanding the short- and long-term effects of the COVID-19 pandemic on the overdose crisis** (Cerda, Magdalena/Friedman, Samuel)
  
  This study aims to identify what characteristics put people at greater risk of drug-related overdose following local exposure to the COVID-19 pandemic, and the types of policies and services with the greatest potential to buffer people who use drugs from the adverse effects of such a major societal crisis.

- **R34 – Adaption of the STAIR-NT Trauma Intervention for Polysubstance Populations** (Bunting, Amanda)
  
  This project adapts an existing evidence-based post-traumatic stress disorder (PTSD) intervention, skills training in affective and interpersonal regulation with narrative therapy (STAIR-NT), via a massed treatment model (i.e., condensed treatment schedule) for patients in methadone maintenance treatment who are engaged in illicit opioid–stimulant polysubstance use.
• **R00 – Joint impacts of local alcohol and cannabis laws and outlet densities on violence** (Matthay, Ellicott)

The goal of this project is to evaluate the causal effects of local alcohol and cannabis policies on neighborhood-level densities of alcohol and cannabis outlets, and in turn, the interactive causal effects of these outlet densities on rates of self-harm and assault injuries in California.

• **K01 – Assessing the Impact of Overdose Prevention Centers as a Polysubstance Use and Behavioral Health Intervention in New York City** (Allen, Bennett)

This study aims to evaluate the impact of the New York City overdose prevention centers, a novel harm reduction intervention, on patient-level polysubstance overdose risk and mental health services use.

• **K01 – Beyond Treatment Initiation: Enhancing Opioid Use Disorder Care Transitions Across Health System Touchpoints** (Krawczyk, Noa)

The proposed research aims to address a lack of knowledge regarding effective strategies for transitioning opioid use disorder patients from interventions that initiate medications for opioid use disorder in hospital settings to ongoing treatment in the community.

• **K01 – Intersectional Stigma Experiences, Pre-exposure Prophylaxis (PrEP), and Other Service Use Among People Who Inject Drugs** (Walters, Suzan)

The objective of the study is to identify sub-populations of people who inject drugs that display different patterns of intersectional stigma due to drug use, race/ethnicity, sexual identity, gender, criminal legal involvement, and poverty, and identify associations between these sub-populations and pre-exposure prophylaxis (PrEP) for HIV prevention care continuum engagement.

• **K01 – Development of a novel polysubstance assessment tool for vulnerable subpopulations** (Bunting, Amanda)

This study uses a rigorous mixed-method approach to develop and validate a novel polysubstance use assessment tool for use with underserved subpopulations.

**Publications**

The Center for Opioid Epidemiology and Policy faculty and students have published 382 papers since its launch in 2018. Researchers in the Center publish on a wide range of topics related to the opioid crisis, polysubstance abuse, and clinical approaches to addressing addiction and overdose.

Recent publications of note include the following:


• Allen, Bennett, et al, *PROVIDENT: Development and validation of a machine learning model to predict neighborhood-level overdose risk in Rhode Island*, *Epidemiology* (2024)


• Friedman, Samuel, Co-editor for Special Focus issue of *Frontiers in Sociology*, *The outbreak and sequelae of the increase in opioid use in the United States, Canada and beyond* (2022)


• Matthay, Ellicott, et al, *A Spatiotemporal Analysis of the Association of California City and County Cannabis Policies with Cannabis Outlet Densities*, *Epidemiology* (2022)


• Walters, Suzan, et al, *Intersectional stigma as a fundamental cause of health disparities: A case study of how drug use stigma intersecting with racism and xenophobia creates health inequities for Black and Hispanic persons who use drugs over time*, *Stigma and Health* (2023)

Informing National Priorities in Policy and Practice

The Center for Opioid Epidemiology and Policy seeks to inform evidence-based policies and health service approaches to prevent opioid misuse, disorder, and overdose in populations nationally and globally through engagement with federal, state and local stakeholders. A few examples of COEP’s role in shaping the national conversation around drug policy and practice include:

- In 2024, the Substance Abuse and Mental Health Services Administration (SAMHSA) released a new rule revising long-standing policies around treatment of opioid use disorder. The new policy was informed by COEP research and policy translation work, including the National Liberating Methadone conference hosted by NYU Langone that took place in September of 2023. The new policy cited research by multiple COEP faculty including Noa Krawczyk, Ayana Jordan, Bennett Allen and Magdalena Cerdá.

- Spruha Joshi, former COEP postdoctoral fellow, along with COEP faculty Magdalena Cerdá and Corey Davis, published the first two papers on the impact that decriminalizing low-level drug possession in Oregon and Washington has had on arrests¹ and overdose². These findings were extensively covered by major national outlets including The Washington Post, NPR, Time, Newsweek, The New York Times, Axios, and many others and they have informed state drug policy. For example, Spruha Joshi participated in a Congressional briefing to Democratic congressional staff about decriminalization of drugs and she and Corey Davis presented at a symposium that was attended by members of the Oregon state legislature.

- Magdalena Cerdá –
  - Joined and led an Expert Group to advise the National Academy of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic on integrating social determinants of health into overdose prevention, substance use disorder treatment, harm reduction, and recovery efforts.
  - Joined the committee drafting the National Academies of Sciences, Engineering and Medicine (NASEM) consensus report on the Public Health Consequences of Changes in the Cannabis Landscape and served on the planning committee for the NASEM workshop, “Methadone Treatment for Opioid Use Disorder: Examining Federal Regulations and Laws.”

- Noa Krawczyk led and hosted a national conference on methadone treatment for opioid use disorder that included members of multiple federal and state policy agencies, including the Substance Abuse and Mental Health Services Administration (SAMHSA), the U.S. Congress House of Representatives, and the NY Office of Addiction Services and Supports (OASAS).

² [https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2809867](https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2809867)
• Ellicott Matthay was appointed to the California Department of Cannabis Control’s Cannabis Advisory Committee (DCC CAC) in August 2022 and the Massachusetts Council on Gaming and Health and Institute on Consumer Health’s Cannabis Expert Research Panel to advise each state agency on cannabis policy and regulatory decision-making.

• Suzan M. Walters presented “Needs Assessment Results” to the Hispanic Alliance for Prevention Steering Committee, served as a Harm Reduction Fellow with the Progressive Policy Institute, and participated in the Heroin Task Force on Long Island.

• Amanda Bunting was appointed to the PhenX Working Group on Medical Cannabis, Polysubstance Use and Recovery and also appointed to serve as the Research Chair of the Academic Consortium on Criminal Justice Health.

Events and Seminars

The Center hosts monthly seminars along with larger conferences and symposia. COEP has reached 3,504 attendees across 49 events.

Polysubstance Use Symposium

The Center for Opioid Epidemiology and Policy hosted the first ever Polysubstance Use Symposium in October 2022. This event, funded by NIDA and led by Dr. Amanda Bunting, accelerated knowledge of polysubstance use (i.e., the use of two or more substances) by bringing together an interdisciplinary group of 127 stakeholders spanning 20 U.S. states and Canada, with an emphasis on opportunities for early career and underrepresented researchers.

Liberating Methadone: Building a Roadmap and Community for Change Conference

In September 2023, COEP hosted the first ever Liberating Methadone: Building a Roadmap and Community for Change Conference. It was led by Drs. Noa Krawczyk and Ayana Jordan, and funded by Pew Charitable Trusts, Vital Strategies, NIDA, and NYU-H+H Clinical and Translational Science Institute. The conference brought together stakeholders such as physicians, researchers and people with lived or living experience with substance use disorder and methadone to exchange ideas on how to improve access to and use of methadone. The conference hosted 255 in-person attendees, over 560 virtual attendees, and 31 travel scholarship winners, with participants spanning 44 U.S. states and nine countries. As an output of the
conference, two working groups are currently generating a report with conference proceedings and actionable recommendations for policy and clinical practice with publication and a dissemination campaign expected later in 2024.

Education and Training

The Center for Opioid Epidemiology & Policy places a particular focus on educating and training the next generation of researchers through our pre- and post-doctoral student engagement, as well as teaching activities.

The Center has mentored 8 postdoctoral fellows as well as 7 predoctoral students since it was founded in 2018. Seven postdoctoral fellows transitioned into faculty roles, while one postdoctoral fellow transitioned into a research scientist role at a leading research institution. While at COEP, students and fellows have published more than 50 papers.

Pilot Project Grant Program

The Center established the first annual Pilot Project Grant Program in Fall 2019, soliciting applications from junior faculty at the assistant professor level, postdoctoral fellows, and students within the NYU system. Since that time, 32 PIs have submitted proposals, and 9 pilot grants totaling $78,950 have been awarded.

The 9 pilot projects, some still underway, have led to impressive results that move the field forward:

- 11 publications
- 2 grant awards – R34 and NIDA Diversity Supplement to an R01, and 1 submission pending final determination for an R03

Some examples of pilot awards include:

- Ji Chang, PhD – Racial Disparities in Access to Hospital-based Opioid Services Before and During Covid-19
- Tarlise Townsend, PhD & John R. Pamplin, PhD – Pathways to racial disparities in the effects of Good Samaritan Laws: A mixed methods study
- Julian Santaella-Tenorio, DVM, MSc, DrPH – Opioid treatment programs and their impact on rates of opioid overdoses and access to medication across racial/ethnic and gender groups: a county level analysis in New York State
- David Frank, PhD – Stakeholders' perceptions of Opioid Substitution Treatment: Factors influencing patient uptake and retention during the overdose crisis era
Other Center Highlights

COEP faculty, students and staff have received honors and participated in activities that raise the profile of the Center’s work as well as the work at NYU Langone Health. Examples include:

- Center faculty, staff, predoctoral students, and postdoctoral students have presented at 75 conferences and poster sessions.

- Amanda Bunting was awarded a HEAL Director’s Trailblazer Award, which recognizes HEAL-funded researchers in the early to middle stages of their careers who are applying an innovative approach in their research or expanding research into addressing the pain and opioid crisis in new directions.

- Magdalena Cerdá made the list of most cited researchers on the Clarivate Analytics’ Highly Cited Researchers 2022 list, was profiled by the *Lancet Psychiatry* for her opioid epidemiology and social justice work, and the American *Journal of Epidemiology* (AJE) and the Society for Epidemiologic Research (SER) selected “Spatiotemporal analysis of the association between pain management clinic laws and opioid prescribing and overdose deaths” as one of the articles of the year that are at the cutting edge of epidemiologic science and represent scholarship that is truly distinguished.

- Noa Krawczyk and Jennifer McNeely presented at the National Academy of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic’s “Workshop on Intervening on Social Determinants of Substance Use Disorders: Lessons Learned for the Healthcare System” on three concrete strategies that health systems could adopt to address social determinants of health and improve outcomes for people with opioid use disorder.

- Ellicott Matthay presented to a National Academies of Sciences, Engineering and Medicine committee on the Public Health Consequences of Changes in the Cannabis Policy Landscape, addressing changes and impacts of the local cannabis policy landscape in California following recreational cannabis legalization in 2016.

- Samuel Friedman received the Senior Scholar Award, Division on Drugs and Society, Society for the Study of Social Problems in 2021 and joined Sigma Xi, The Scientific Research Honor Society.

- Bennett Allen received a Fellowship in HIV and Drug Use Prevention Research Ethics through the Fordham Center for Ethics Education and joined the Research Advisory Committee for the Rutgers Center for State Health Policy Integrated Population Health Data Project. He was also appointed NIH Justice Community Opioid Innovation Network (JCOIN) scholar.

- Suzan Walters was selected as a visiting professor at the University of California San Francisco Center for AIDS Prevention Studies, received the junior scholar award from the American Sociological Association Drugs and Society Section in 2022, and was selected to join the 2022 cohort of the Lifespan/Brown Criminal Justice Research Training program.

Communications and Media
Newsletter and Social Media Engagement

Amplifying research findings and disseminating information to a wide audience through our monthly Newsletter and Twitter are two ways COEP expands the reach of our research.

• COEP launched the Epidemiology and Policy Updates newsletter with a listserv distribution of 947 recipients. It showcases significant findings in opioid research, recent developments in opioid policy and, most recently, updates relevant to COVID-19 to engage researchers, policymakers, and advocacy groups in the field of substance use.

• We expanded the social media presence of the Center to 1,594 followers on Twitter through Magdalena Cerdá’s account by promoting recent news and events, posting visual abstracts to showcase faculty research, and engaging with thought leaders in the field of substance use and abuse research.

Thought Leadership in the Media

COEP faculty are routinely quoted in major media outlets, featured in television interviews and approached to share their thought leadership on issues related to the Center’s research.

• Magdalena Cerdá, has been featured in numerous media outlets such as The Los Angeles Times (Researchers Link Opioid Deaths to Marketing By Drugmakers), The Wall Street Journal (Overdose Deaths Likely to Fall for First Time Since 1990), The Washington Post (Medicaid Expansion May Have Saved Thousands from Drug Overdose Deaths, U.S. Life Expectancy Continued to Fall in 2021 as Covid Drug Deaths Surged, and Do Overdose Prevention Centers Work? First U.S. Study Seeks Answers) and NBC News (Latinos Had Been Spared the Worst of the Opioid Crisis, But Now Overdose Deaths Are Skyrocketing).

• Bennett Allen is quoted regarding overdose data in New York City, including What the latest overdose data says about NYC’s efforts to curb the crisis, (Gothamist) and authored a Thirteen.org/PBS OpEd with Magdalena Cerdá, The Overdose Crisis in New York City: We Must Work Together to Ensure Lasting Change.
• Samuel Friedman is often asked to comment on his research and advocacy work, including How Isolation Can Affect Substance Users (BronxNet), Activism Made AIDS Treatment More Accessible —That’s What It’ll Take for COVID (Truthout), Awareness and Knowledge of PrEP Varies by Rural vs. Urban Setting Among People Who Inject Drugs and The CDC Is Beholden to Corporations and Lost Our Trust. We Need to Start Our Own (The Guardian).

• Noa Krawczyk is active in advocating for evidence-based treatment approaches to substance use disorders, including New Data Strongly Support Opioid Agonists for Addiction (Medscape), Native American Tribe Plans to Build an Opioid Treatment Center, but Neighbors Have Vowed to Block It (The Washington Post), Years into a Nationwide Overdose Epidemic, Many with Opioid Addiction Still Aren’t Getting Treatment Medication, a New Study Finds (The Philadelphia Inquirer), Under New Rules, Methadone Clinics Can Offer More Take-Home Doses. Will They? (STAT News), Most People with Opioid Use Disorder Don’t Get Meds for It, but These Three Changes Could Help (The Hill) and she was featured on CSPAN Washington Journal in Noa Krawczyk on the Fentanyl Epidemic.

• Ellicott Matthay has been interviewed and featured on a podcast related to her work, Alcohol vs. edibles: Is one worse for your health than the other? (Eating Well) and the SERious Epidemiology podcast, How great are case-control studies with Ellie Matthay.

• Suzan Walters has been quoted in media, particularly regarding stigma, including Here’s How the End of the COVID-19 Public Health Emergency Could Affect You, According to MDs (Well + Good), Provider Stigma Can Prevent Injection Drug Users from Receiving PrEP (Contagion Live) and Intersectional Stigma: Rural America, HIV PrEP, and Injection Drug Use (Contagion Live).